Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 11/20 | 0.50 |
| ▸ | BCL2 | P10415 | 3/20 | 0.48 |
| ▸ | BCL2L1 | Q07817 | 3/20 | 0.48 |
| ▸ | ALB | P02768 | 1/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 4/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.46 |
| ▸ | PDE6D | O43924 | 2/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | AKT2 | P31751 | 1/20 | 0.45 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24745286 | 0.99 | MCL1 (0.51) | MCL1BCL2BCL2L1ALBPTK2 | |
| SCHEMBL24745339 | 0.97 | MCL1 (0.51) | MCL1BCL2BCL2L1ALBPTK2 | |
| SCHEMBL30001329 | 0.97 | MCL1 (0.51) | MCL1BCL2BCL2L1ALBPTK2 | |
| SCHEMBL24773807 | 0.96 | MCL1 (0.47) | MCL1BCL2BCL2L1ALBPTK2 | |
| SCHEMBL24744625 | 0.92 | MCL1 (0.49) | MCL1ALBPDE6D | |
| SCHEMBL30000212 | 0.92 | MCL1 (0.56) | MCL1BCL2BCL2L1ALB | |
| SCHEMBL24745152 | 0.92 | MCL1 (0.56) | MCL1BCL2BCL2L1ALB | |
| SCHEMBL24773175 | 0.91 | MCL1 (0.53) | MCL1BCL2BCL2L1 | |
| SCHEMBL30001556 | 0.91 | MCL1 (0.53) | MCL1BCL2BCL2L1 | |
| SCHEMBL24745646 | 0.90 | AKT1 (0.50) | MCL1BCL2PDE6DAKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4347579-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | Captor Therapeutics S.A. (PL) | 2024-04-10 | — | — | EP | disclosed |
| WO-2022255888-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022255888-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022253713-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022253713-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2022-12-08 | — | — | WO | disclosed |